Shaily Engineering promoter Vanita Nagda sells entire 2.27% stake

Tipsheet Editorial — Fri, 19 Jun 2026 11:52:52 GMT

The sale, valued at about ₹288 crore, was executed on June 18. The promoter group's aggregate stake falls.

What’s new

Vanita L. Nagda sold her entire 10,43,510 shares (2.27% equity) on June 18.
The sale was disclosed under SEBI Takeover Code; executed on BSE and NSE.
Nagda, based in Canada, has exited her position completely.

Why it matters

For a mid-cap with a market cap of ₹12,744 crore, a promoter completely cashing out a 2.27% stake worth ₹288 crore is material. It reduces promoter commitment and could weigh on sentiment, even if the company's fundamentals remain intact.

What we’re watching

Whether other promoter group members follow suit or consolidate.
Any subsequent block deals or change in shareholding pattern.
Impact on stock liquidity given the size of the disposal.

The full read

Shaily Engineering promoter Vanita L. Nagda sold her entire 2.27% equity stake (10,43,510 shares) through open market transactions on June 18. The sale, valued at roughly ₹288 crore, cuts the promoter group's total holding, though the company's market cap is ₹12,744 crore. Nagda, a Canada-based shareholder, has fully exited. While Shaily's fundamentals (revenue growth of 8.7% and PAT growth of 40.5%) remain solid and its semaglutide pen launch in Canada is a fresh catalyst, a promoter completely cashing out at this scale is a signal that investors cannot ignore. The open question is whether this is an isolated move or a precursor to further offloading.

Primary source: BSE · NSE

Shaily Engineering launches semaglutide pens in Canada

Tipsheet Editorial — Wed, 27 May 2026 12:10:45 GMT

The company enters regulated drug delivery markets with two commercial launches and tentative US FDA approval, while healthcare revenue jumps 139%.

What’s new

Commercial launch of pen injectors for generic semaglutide in Canada via two customers.
Tentative US FDA approval secured for the company's drug delivery devices.
New supply agreement signed with a Korean firm for semiconductor trays.

Why it matters

Shaily is successfully pivoting from general plastics into high-margin regulated healthcare and semiconductor segments. The 139% surge in healthcare revenue confirms that these specialized bets are already scaling rapidly.

What we’re watching

Production line ramp-up speeds to meet the 36 million unit target.
Conversion of tentative US FDA approval into full commercial authorization.
Margin impact from the new semiconductor tray supply contract.

The full read

Shaily Engineering Plastics is moving into regulated drug delivery markets. The company confirmed the commercial launch of its pen injectors for generic semaglutide in Canada, supported by two customers. It also received tentative US FDA approval, a key step for its healthcare expansion. Financials reflect this shift: healthcare revenue surged 139% to ₹393 crore for the year, helping drive total consolidated revenue up 26% to ₹991 crore and net profit up 83% to ₹170 crore. Beyond healthcare, the company is diversifying into electronics and semiconductors, having started supplies to a consumer electronics client and signed a deal for semiconductor trays with a Korean partner. Management is now targeting 36 million units for semaglutide pens this year. Success hinges on how quickly they can bring new production lines online to meet that volume.

Primary source: BSE · NSE

Shaily Engineering Plastics Ltd. (SHAILY) — Tipsheet

Shaily Engineering promoter Vanita Nagda sells entire 2.27% stake

What’s new

Why it matters

What we’re watching

The full read

Shaily Engineering launches semaglutide pens in Canada

What’s new

Why it matters

What we’re watching

The full read